AstraZeneca entered a global licensing and co-development collaboration with Daiichi Sankyo for Enhertu (trastuzumab deruxtecan), a HER2-directed antibody-drug conjugate. AstraZeneca paid $1.35 billion upfront with up to $5.55 billion in regulatory and sales milestones, for a total potential deal value of $6.9 billion. Daiichi Sankyo retained exclusive rights in Japan and manufacturing responsibility.
Did it work? Outcome assessment
Strategic verdict
Achieved Stated Rationale
Financial impact
Accretive
Pipeline outcome
Assets Advanced
Assessment window: 5yr post-close.
Key facts
AnnouncedMar 28, 2019
ClosedMar 29, 2019
Deal value$6.9B
Deal typeLicensing/Option
Therapeutic areaOncology
IndicationsBreast Cancer, Gastric Cancer, Non-Small Cell Lung Cancer